Rami Manochakian, MD, FASCO

DocwireNews

Rami Manochakian, MD, FASCO, of the Mayo Clinic, Florida, who served as the lung cancer panelist during Advancements in Oncology, discusses what oncologists need to know about advances in lung cancer treatment and the latest data.
Dr. Manochakian joined The Oncology Brothers, Rahul Gosain, MD, MBA, and Rohit Gosain, MD, during their <a href="https://www.docwirenews.com/conference/advancements-in-oncology-lung-cancer" target="_blank" rel="noopener">Advancements in Oncology</a> event held on June 1 to discuss major updates in lung cancer treatment from the <a href="https://www.docwirenews.com/conference/asco-2024-lung-cancers-today" target="_blank" rel="noopener">2024 American Society of Clinical Oncology Annual Meeting</a>.
Major topics of discussion included readouts from phase 3 trials in lung cancer that were presented during the annual meeting. For example, the 5-year follow-up of the phase 3 CROWN trial, which compared lorlatinib with crizotinib in patients with advanced non-small cell lung cancer (NSCLC), showed the median progression-free survival (PFS) had yet to be reached in patients receiving lorlatinib.
Dr. Manochakian discussed the implications of the study, noting that questions remain about treatment sequencing with lorlatinib, as there are no head-to-head comparisons of it with similar treatments, such as alectinib and brigatinib.
He also spoke about the LAURA trial, which was presented by Suresh S. Ramalingam, MD, FACP, FASCO, of the Winship Cancer Institute of Emory University, during the plenary session on June 2.
The <a href="https://www.docwirenews.com/post/phase-3-laura-trial-primary-results-highlighted-in-plenary-session">LAURA trial</a>, a double-blinded and placebo-controlled phase 3 trial, assessed the efficacy and safety of osimertinib in adults with unresectable stage III EGFR-mutated NSCLC who received definitive platinum-based concurrent or sequential chemoradiotherapy and did not have progression.
Dr. Manochakian spoke about how the LAURA trial may shape practice, explaining that it’s important for community oncologists and any oncology provider to recognize that the regimen used in LAURA is “probably a new standard of care” for this population of patients.
Beyond LAURA, he discussed the surprising results of the<a href="https://www.docwirenews.com/post/investigators-present-primary-results-of-paloma-3-study-comparing-subcutaneous-iv-administration-of-amivantamab" target="_blank" rel="noopener"> phase 3 PALOMA-3 trial</a>, which evaluated subcutaneous amivantamab plus lazertinib versus intravenous (IV) amivantamab plus lazertinib in patients with refractory EGFR-mutated, advanced NSCLC. The analysis, presented as an oral abstract at the annual meeting by Natasha B. Leighl, MD, FASCO, of the Princess Margaret Cancer Centre and the University of Toronto, showed that patients receiving subcutaneous amivantamab had longer overall survival and PFS than those receiving IV amivantamab.
Dr. Manochakian spoke about the practical implications of the study, explaining that subcutaneous injections are “definitely much easier” for patients, oncology providers, and institutions, as they are faster than IV administration. The reduced administration time, combined with the results showing improved survival and reduced adverse events associated with the subcutaneous injection, make the PALOMA-3 trial results “potentially practice-changing,” he said.

Rob Dillard

SURMOUNT-OSA: Tirzepatide Benefits Sleep Apnea Patients With Obesity

ADA 2024

Common Cholesterol-Lowering Drug May Slow the Progression of Diabetic Retinopathy

Katy Marshall

Efficacy, Safety of Stereotactic Body Radiotherapy for Patients With HCC

Unresectable HCC

Latest News

Dr. Rami Manochakian Discusses Major Lung Cancer Updates

Advancements in Oncology

Dr. Manochakian discusses the implications of recent phase 3 trials in lung cancer.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Onc Brothers Event

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Diabetes

Oncology

Neurology

Rheumatology

Gastroenterology

Pulmonology

Ophthalmology

Infectious Diseases

— HIV

Health and Wellness

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe